Valbiotis【ALVAL】銘柄情報

Valbiotis SA (ALVAL) 銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

1.114

( 1.27% )

買値

1.114

売値

1.136

出来高

143,629

1.10 日の範囲 1.156

0.535 52 週間の範囲 1.296

時価総額

26.354M

前日終値

1.10

始値

1.102

時刻

820

1.114

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

180,518 €

発行済株式数

23,657,340

配当利回り

PER

-2.48

1 株当たり利益 (EPS)

-0.47

歳入

905k

純利益

-9.42M

Valbiotis SA engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France and Asia. The company offers supplements for immunity and vitality, health and wellbeing, metabolic and cardiovascular health, and beauty and physical comfort. It al... Valbiotis SA engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France and Asia. The company offers supplements for immunity and vitality, health and wellbeing, metabolic and cardiovascular health, and beauty and physical comfort. It also develops TOTUM-63 for the reduction of fasting blood glucose and treatment of type 2 diabetes; TOTUM-854, which is in Phase II/III clinical trials for reducing systolic blood pressure; and TOTUM-448 for the reduction of hepatic steatosis. Additionally, the company offers e-commerce delivery service in Belgium and Luxembourg. Valbiotis SA was incorporated in 2014 and is based in Périgny, France. 詳細を表示

セクター

Healthcare

業界

Biotechnology & Life Sciences

ウェブサイト

www.valbiotis.com

本社

Périgny, France

設立

2026

Valbiotis SA is listed in the Healthcare sector of the ユーロネクスト with ticker ALVAL. The last closing price for Valbiotis was 1.10 €. Over the last year, Valbiotis shares have traded in a share price range of 0.535 € to 1.296 €.

Valbiotis currently has 23,657,340 shares in issue. The market capitalisation of Valbiotis is 26.35 € million. Valbiotis has a price to earnings ratio (PE ratio) of -2.48.

Valbiotis meldet durchschlagenden Erfolg der internationalen multizentrischen Phase-II/III-Studie REVERSE-IT zu TOTUM•63: nachgewiesene Wirksamkeit bei Hauptrisikofaktor für Typ-2-Diabetes

Die Studie erreichte ihr Ziel beim primären Endpunkt, der Senkung des Nüchternblutzuckers – Risikofaktor für Typ-2-Diabetes, bei einer...

Valbiotis annonce le large succès de l’étude clinique de Phase II/III internationale multicentrique REVERSE-IT sur TOTUM•63 : efficacité démontrée sur le principal facteur de risque du diabète de type 2

L’étude atteint son objectif sur le critère principal, la réduction de la glycémie à jeun, facteur de risque du diabète de type 2, à la dose...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0.036	3.33951762523	1.078	1.25	1.052	219987	1.15768028	DE
4	0.193	20.9554831705	0.921	1.25	0.917	164566	1.1049631	DE
12	0.072	6.90978886756	1.042	1.25	0.88	156526	1.05041235	DE
26	0.408	57.790368272	0.706	1.296	0.627	252158	0.98258734	DE
52	-0.116	-9.43089430894	1.23	1.296	0.535	236520	0.91769277	DE
156	-4.006	-78.2421875	5.12	7.5	0.535	119402	1.6495746	DE
260	-6.186	-84.7397260274	7.3	7.5	0.535	73684	1.88518011	DE